Metagenomi (NASDAQ:MGX – Get Free Report) posted its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.18), FiscalAI reports. The firm had revenue of ($0.26) million during the quarter, compared to the consensus estimate of $3.01 million. Metagenomi had a negative return on equity of 59.05% and a negative net margin of 384.61%.
Metagenomi Stock Performance
MGX traded up $0.01 during mid-day trading on Wednesday, reaching $1.22. The stock had a trading volume of 69,615 shares, compared to its average volume of 206,200. The stock has a market capitalization of $45.74 million, a P/E ratio of -0.49 and a beta of 0.66. Metagenomi has a 52 week low of $1.13 and a 52 week high of $3.95. The firm’s fifty day simple moving average is $1.23 and its two-hundred day simple moving average is $1.37.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the stock. Weiss Ratings cut shares of Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 23rd. Wall Street Zen raised Metagenomi from a “strong sell” rating to a “sell” rating in a report on Monday, July 20th. Chardan Capital assumed coverage on Metagenomi in a report on Tuesday, July 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on Metagenomi to $7.00 and set an “overweight” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Metagenomi presently has an average rating of “Moderate Buy” and an average price target of $6.33.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd grew its position in shares of Metagenomi by 353.4% during the 4th quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock worth $112,000 after buying an additional 53,778 shares during the period. Quadrature Capital Ltd bought a new position in Metagenomi in the fourth quarter valued at approximately $55,000. Bridgeway Capital Management LLC grew its holdings in Metagenomi by 102.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after acquiring an additional 200,000 shares during the period. Panagora Asset Management Inc. acquired a new stake in Metagenomi during the 4th quarter worth $53,000. Finally, Wells Fargo & Company MN raised its position in shares of Metagenomi by 16.1% during the 4th quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock valued at $192,000 after acquiring an additional 16,402 shares during the last quarter.
Metagenomi Company Profile
Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.
Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.
Featured Stories
- Five stocks we like better than Metagenomi
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
